ArticleTherapeutics and clinical risk management2015
Canagliflozin-induced pancreatitis: a rare side effect of a new drug.
Article in Therapeutics and clinical risk management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Review
- Dapagliflozin-Induced Acute Pancreatitis: A Case Presentation and Review of the Literature.Cureus · 2024Article
- SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.International journal of clinical pharmacy · 2022Review
- Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on food and drug administration adverse event report system database.Frontiers in pharmacology · 2022Article
- Probable Dapagliflozin-Associated Acute Pancreatitis.Diabetes spectrum : a publication of the American Diabetes Association · 2022Article
- Article
- Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors.ACG case reports journal · 2021Article
- Management of Type 2 Diabetes: Current Strategies, Unfocussed Aspects, Challenges, and Alternatives.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Review
- Dapagliflozin-Induced Acute Pancreatitis: A Case Report and Review of Literature.Case reports in endocrinology · 2020Article
- Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes.Current diabetes reports · 2019Review
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.BMJ (Clinical research ed.) · 2018Article
- An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.Current opinion in endocrinology, diabetes, and obesity · 2017Review
- The Current Status of New Antidiabetic Drugs.Journal of pharmacopuncture · 2016Article
- Are the Newer Antidiabetic Agents Worth the Cost?Journal of clinical and diagnostic research : JCDR · 2016Article
- Pancreatitis in a 57-Year-Old Female Two Weeks After Initiation of Empagliflozin.AACE clinical case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pancreatitis is most commonly attributed to gallstones, alcohol abuse, and metabolic disorders such as hyperlipidemia and hypercalcemia. Medications are an infrequent yet commonly overlooked etiology of pancreatitis. Although several drugs have been implicated, antidiabetic agents are a rare cause for drug-induced pancreatitis. Canagliflozin is a new drug in the class of SGLT-2 inhibitors used for the treatment of type 2 diabetes mellitus. Serious reported side effects include renal impairment, hyperkalemia, and hypotension. Pancreatitis as a result of canagliflozin, however, is exceedingly rare. Here we describe a case of a 33-year old female who presented with severe acute pancreatitis in the setting of recent initiation of canagliflozin. Given the timing of her presentation and after excluding all other possible etiologies, it was determined that canagliflozin was the likely source of her illness. This case highlights the importance of identifying drug-induced pancreatitis, especially in novel drugs, as it is commonly neglected in patients with multiple medical comorbidities and those taking numerous medications. Prompt identification of drug-induced pancreatitis can improve management as well as decrease morbidity and mortality in these individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.